Published Paper Details:

The prevalent endocrine and metabolic condition known as Polycystic Ovarian Disease (PCOD), or Polycystic Ovary Syndrome (PCOS), affects women who are of reproductive age. Due to intricate connections between genetic, hormonal, and environmental variables, it is typified by hyperandrogenism, chronic anovulation, and polycystic ovarian morphology. Its pathogenesis is primarily characterized by insulin resistance and dysregulation of the hypothalamic-pituitary-ovarian (HPO) axis, which lead to metabolic disorders like obesity, dyslipidemia, and hyperinsulinemia. Infertility, hirsutism, irregular menstrual periods, and psychological problems including anxiety and depression are among the symptoms that women come with in clinical settings. Based on imaging and biochemical analysis, the diagnosis is made using the Rotterdam, NIH, or AE-PCOS criteria. A comprehensive and customized strategy combining pharmaceutical interventions, lifestyle changes, and nutraceutical support is needed for management. While natural substances like myo-inositol, N-acetylcysteine, alpha-lactalbumin, and Ceylon cinnamon show promise in enhancing insulin sensitivity and lowering oxidative stress, insulin-sensitizing medications like metformin continue to be the mainstay of treatment. In order to enhance long-term metabolic and reproductive results, future developments will prioritize precision medicine, gut microbiota modification, and treatments based on nanotechnology. In order to lower problems and improve the general quality of life for women with PCOD, early diagnosis and multidisciplinary therapy are crucial.